BioDuro and Roche extend collaboration
BioDuro and Roche are to expand an existing agreement to provide drug discovery services.
BioDuro and Roche are to expand an existing agreement to provide drug discovery services.
"Presently, there is intense competition within the CRO industry for outsourcing and drug discovery services, and the expectation is that they will deliver problem-solving skills and innovation in both chemistry and biology," said Robert Goodnow, Roche's global head of medicinal chemistry outsourcing. "We selected BioDuro due to its demonstrated excellent performance in synthetic chemistry and ability to deliver integrated medicinal chemistry services."
Headquartered in Basel, Switzerland, Roche is a leading research-focused healthcare group in the fields of pharmaceuticals and diagnostics.
John Oyler, chief executive and co-founder of BioDuro, said: "BioDuro is pleased to build upon this existing collaboration and work closely with the experienced team at Roche to aid in the development of novel therapeutics. Our partnership demonstrates the strength of our innovative, fully integrated r&d service platform, and is a true testament to the calibre of scientists that have joined our team.
BioDuro is a US-based, fully-integrated, end-to-end, life science, research services company with a team of 580 in Beijing, China.